Influenza B is one of the three major subtypes of influenza viruses, other than Influenza A and Influenza C. While Influenza A attacks several species in cycles of both epidemics and pandemics, Influenza B attacks only humans and is nearly always associated with seasonal flu outbreaks. Although the Influenza B virus tends to cause less severe disease compared to its cousin, Influenza A, it can cause severe complications in some groups, which include the elderly, very young children, pregnant women, and persons with chronic health conditions.
The two major lineages of Influenza B are B/Victoria and B/Yamagata, and the strain circulating strains from these two lineages can vary by flu season, so it is very important to have both lineages included in the annual influenza vaccine in order to provide broad protection. Because of its more limited range of hosts, Influenza B remains a major cause of morbidity and mortality, particularly during flu seasons.
Influenza B virus, like Influenza A, primarily targets the upper respiratory system such as the nose, throat, and lungs. The virus enters host cells by binding to sialic acid receptors on the surface of respiratory epithelial cells with the help of the viral hemagglutinin (HA) protein. Upon infection of the host cell, the virus continues replicating causing cell damage and leading to an immune response. The subsequent inflammation in the respiratory tract results in typical flu symptoms - that is, fever, cough, sore throat, muscle aches, and fatigue.
Unlike Influenza A, for instance, which undergoes high antigenic shifts, and hence, leads to the appearance of new pandemics; Influenza B, by contrast, mutates relatively slowly through antigenic drift--an accumulation of mutations within the proteins that are slow in nature, leading to a reduced potential for pandemics but may occur with severe outbreaks.
Although most persons recover from Influenza B in one to two weeks, some populations are more prone to complications, such as bronchitis, pneumonia, asthma exacerbation, and, rarely, encephalitis.
The treatment of Influenza B is similar to that of Influenza A, mainly antivirals, caring support, and vaccination against the flu. Antivirals are most potent during 48 hours from onset of symptoms; they may reduce the length of the illness and risk of complications.
Oseltamivir (Tamiflu): It is the most commonly used antiviral agent not only for Influenza A but also for B. Oseltamivir works by inhibiting the neuraminidase enzyme, which is required to release newly produced virus particles from the infected cells.
Zanamivir (Relenza): An inhaled neuraminidase inhibitor that is effective in both A and B. These are very useful for patients who cannot take oral medication.
Reserve peramivir (Rapivab) for inpatient use when clinical judgment has determined that an influenza patient requires treatment with an intravenous neuraminidase inhibitor.
2. Endonuclease Inhibitors: Acting on the viral cap-dependent endonuclease used for the synthesis of viral mRNA
One such agent is baloxavir marboxil (Xofluza), a novel antiviral drug that target the cap-dependent endonuclease enzyme. Active against Influenza A and B viruses, it can be administered as a single dose. Its potential to significantly reduce the duration of symptoms and shedding has been established by clinical studies on baloxavir.
3. Supportive Care:
Mild Influenza B is recovered by most patients with just rest, hydration, and over-the-counter medications that can help reduce fever and aches, such as acetaminophen or ibuprofen. In more serious cases, especially the one with complications like pneumonia, they are hospitalized for respiratory treatments and care.
4. Vaccination:
The Influenza B vaccine is licensed only for annual production and prevention against Influenza B is through the annual influenza vaccines. Quadrivalent flu vaccines offer immunity against two lineages of Influenza B (B/Victoria and B/Yamagata) and two types of influenza A. Vaccination is particularly crucial in risk groups to reduce the incidence of serious illness and complications.
Mechanism of Action |
Key Drugs/Technologies |
Companies/Organizations Involved |
---|---|---|
Neuraminidase Inhibition |
Oseltamivir (Tamiflu), Zanamivir (Relenza), Peramivir (Rapivab) |
Roche, GlaxoSmithKline (GSK), BioCryst Pharmaceuticals |
Cap-Dependent Endonuclease Inhibition |
Baloxavir marboxil (Xofluza) |
Shionogi, Roche |
RNA Polymerase Inhibition |
Favipiravir (Avigan), Pimodivir |
Fujifilm Toyama Chemical, Johnson & Johnson |
Monoclonal Antibodies Targeting Hemagglutinin |
MHAA4549A, VIS410 |
Genentech (Roche), Visterra |
Universal Influenza Vaccine |
M-001 Vaccine |
BiondVax Pharmaceuticals |
Host-Targeted Therapies |
Nitazoxanide |
Romark Laboratories |
Combination Antiviral Therapies |
Oseltamivir + Baloxavir |
Roche, Shionogi |
CRISPR-Based Antiviral Therapies |
CRISPR/Cas9 antiviral system |
Broad Institute, MIT, Multiple biotech companies |
While Influenza B is less likely to undergo significant genetic mutations than Influenza A, the looming specter of seasonal epidemics has stimulated interest. Furthermore, the threat of antiviral resistance supports the development of new treatments as well as prevention efforts. There are now a number of clinical trials studying new antivirals, monoclonal antibodies, and next-generation vaccines as these may provide broader and longer-lasting protection against Influenza B.
1. Next-Generation Antivirals:
Treatment of Influenza B
The treatment of Influenza B is similar to that of Influenza A, mainly antivirals, caring support, and vaccination against the flu. Antivirals are most potent during 48 hours from the onset of symptoms; they may reduce the length of the illness and risk of complications.
Oseltamivir (Tamiflu): It is the most commonly used antiviral agent not only for Influenza A but also for B. Oseltamivir works by inhibiting the neuraminidase enzyme, which is required to release newly produced virus particles from the infected cells.
Zanamivir (Relenza): An inhaled neuraminidase inhibitor that is effective in both A and B. These are very useful for patients who cannot take oral medication.
Reserve peramivir (Rapivab) for inpatient use when clinical judgment has determined that an influenza patient requires treatment with an intravenous neuraminidase inhibitor.
2. Endonuclease Inhibitors: Acting on the viral cap-dependent endonuclease used for the synthesis of viral mRNA
One such agent is baloxavir marboxil (Xofluza), a novel antiviral drug that targets the cap-dependent endonuclease enzyme. Active against Influenza A and B viruses, it can be administered as a single dose. Its potential to significantly reduce the duration of symptoms and shedding has been established by clinical studies on baloxavir.
3. Supportive Care:
Mild Influenza B is recovered by most patients with just rest, hydration, and over-the-counter medications that can help reduce fever and aches, such as acetaminophen or ibuprofen. In more serious cases, especially the ones with complications like pneumonia, they are hospitalized for respiratory treatments and care.
4. Vaccination:
The Influenza B vaccine is licensed only for annual production and prevention against Influenza B is through the annual influenza vaccines. Quadrivalent flu vaccines offer immunity against two lineages of Influenza B (B/Victoria and B/Yamagata) and two types of influenza A. Vaccination is particularly crucial in risk groups to reduce the incidence of serious illness and complications.
While Influenza B occurs in all age groups, some populations are at a higher risk for more severe illness and complications:
Children: Young children, particularly those younger than 5 years old, are at increased risk for severe pulmonary complications, including pneumonia, because of their immature immunity.
Aged persons: All those above the age of 65 years fall in this category. Their complications are greater with Influenza B, as most have other diseases like heart conditions or diabetes.
Pregnant females: The pregnant mother increases the risk of having severe influenza, and Influenza B might lead to some complications such as preterm labor and later pneumonia.
Immunocompromised patients: The more seemingly immunocompromised patients, which also include most treated cancer and HIV/AIDS affected, tend to have higher risks of developing complications from Influenza B.
Those who have chronic diseases within the pulmonary or cardiovascular systems, like COPD or asthma.
Even with the availability of effective antivirals and vaccines, antimicrobial resistance and vaccine mismatches are significant unmet needs in the treatment of Influenza B. Universal influenza vaccines and new antiviral agents would be just what the doctor ordered to reduce seasonal flu outbreaks. Next-generation antiviral therapies based on technologies like CRISPR-based therapies or monoclonal antibodies also promise a better management of Influenza B.
However, long-term solutions will depend on continued investment in the execution of research and clinical trials for challenges associated with vaccine longevity, antiviral resistance, and the discovery of new therapeutic targets for Influenza B.
1. Introduction to Influenza B
1.1 Overview and Global Impact
1.2 Differences Between Influenza A and B
1.3 Epidemiology and Seasonal Patterns
Pathophysiology of Influenza B
2.1 Viral Entry and Replication
2.2 Immune Response and Symptoms
2.3 Complications and Risk Factors
Current Treatments for Influenza B
3.1 Neuraminidase Inhibitors (Oseltamivir, Zanamivir, Peramivir)
3.2 Cap-Dependent Endonuclease Inhibitors (Baloxavir)
3.3 Supportive Care and Symptom Management
3.4 Annual Influenza Vaccination
Emerging Therapies and Clinical Trials
4.1 Next-Generation Antivirals (Favipiravir, Pimodivir)
4.2 Monoclonal Antibodies (MHAA4549A, VIS410)
4.3 Universal Influenza Vaccines (M-001)
4.4 Combination Antiviral Therapies
4.5 CRISPR-Based Therapies
Patient Demographics and Risk Stratification
5.1 High-Risk Populations (Children, Elderly, Pregnant Women)
5.2 Immunocompromised Individuals
5.3 Chronic Conditions and Comorbidities
Future Directions and Challenges
6.1 Addressing Antiviral Resistance
6.2 Universal Vaccine Development
6.3 New Therapeutic Targets for Influenza B
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
23 October 2024
Hi! Click one of our member below to chat on Phone